media – Page 29 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Merger of two well-known pharmaceutical companies

On October 7, Jiahe Bio announced that it would acquire Yitong Pharmaceuticals by merger. The name of the merged company will be changed to Yitong Jiahe Pharmaceutical Group Co., Ltd. (hereinafter referred to as “Yitong Jiahe”). The transaction is carried out in the form of a share swap. The price of the proposed merger will be fully settled by issuing consideration shares. After the merger is completed, the shareholders of both parties will jointly hold the equity of Yitong Jiahe, and Jiahe Bio will not have any cash expenditure. According to the listing rules, the transaction constitutes a reverse acquisition of Jiahe Bio. In the merged Yitong Jiahe, the original Yitong Pharmaceutical shareholders accounted for 77.43%, and the original Jiahe Bio shareholders accounted for 22.57%. The actual controller of Yitong Pharmaceutical will become the controlling shareholder of Yitong Jiahe. Based on the rules of Chapter 18A of the Hong Kong ...
- Source: drugdu
- 70
- October 10, 2024
PCSK9 antibody marketing application received notification

On September 29, 2024, two acceptance numbers for Junshi Biosciences’s PCSK9 antibody marketing application were notified, indicating that they have not been approved (possibly due to voluntary withdrawal or pending approval). In April 2023, Junshi Biosciences received 4 acceptance numbers for its PCSK9 antibody market application, of which 2 were notified this time, and the other 2 have not yet received results. Four acceptance numbers involve two specifications (pre filled syringes, pre filled automatic syringes) and two indications. This two notifications indicate that a certain specification or indication has not been approved. The competition for PCSK9 targets is particularly fierce. In addition to antibodies from Amgen and Sanofi, PCSK9 antibodies from Sinovac Biotech and PCSK9 siRNA from Novartis have already been approved for marketing. Among them, Novartis’ PCSK9 siRNA only needs to be administered once every six months. For this target, there are more differentiated products under development, including Merck’s ...
- Source: drugdu
- 74
- October 9, 2024
The 2024 “Most Promising New Talent in Biopharmaceuticals” list has been released!

Recently, well-known industry media Endpoint News released the “Biopharma’s Most Exciting Startups in 2024” list, which includes 11 biotechnology companies. These emerging research fields include gene editing, immunotherapy, antibody conjugated drugs (ADCs), weight loss therapy, and multiple other directions. This article will introduce these 11 rising stars (listed in no particular order) to readers, based on this ranking and official information from various companies. Lifordi Immunotherapies is a biotechnology company dedicated to developing ADC therapies for the treatment of autoimmune and inflammatory diseases. Lifordi was founded in 2023 and has secured $70 million in Series A funding from ARCH Venture Partners, 5AM Ventures, and Atlas Venture, with the goal of advancing the main candidate drug LFD-200 into clinical trials and obtaining preliminary data by the end of 2025. Lifordi’s main ADC therapy LFD-200 targets myeloid cells and lymphocytes by targeting highly internalized cell surface facial mask proteins. This therapy has ...
- Source: drugdu
- 94
- October 9, 2024
Cardiovascular device giant, official announcement of split

Recently, Integer Holdings Corporation, the world’s largest CDMO company with deep roots in cardiovascular devices, announced that it will divest its non-medical business. The company has reached an agreement to sell its Electrochem business, which focuses on the energy, military and environmental fields, to Ultralife Corporation for $50 million in cash, and the transaction is expected to be completed by the end of October. Joe Dziedzic, president and CEO of Integer, said that after the transaction is completed, Integer will be a pure medical company with additional cash to repay debt and execute our inorganic growth strategy. Ultralife is an ideal buyer for Electrochem because they are a leader in providing critical power solutions to a variety of industries including energy, defense and environmental markets. As a global medical device CDMO leader, Integer’s medical customers include large multinational medical device OEMs and their subsidiaries, including Abbott, Johnson & Johnson, Boston ...
- Source: drugdu
- 69
- October 9, 2024
The National Medical Insurance Administration responded to the next direction of the centralized procurement of consumables

Recently, the National Medical Insurance Administration issued the “Reply of the National Medical Insurance Administration to Suggestion No. 2090 of the Second Session of the Fourteenth National People’s Congress” (hereinafter referred to as the “Reply”). In the “Reply”, the National Medical Insurance Administration explained the next steps for the centralized procurement of consumables and the implementation of innovative medical devices. In particular, the next steps for local centralized procurement were explained. The “Reply” pointed out that centralized procurement is still in the stage of reform and overcoming difficulties. The National Medical Insurance Administration will further supervise and improve the rules of local centralized procurement, improve the scientificity and standardization of local centralized procurement, and improve the quality and efficiency of procurement. First, expand the scope of the alliance and strengthen national coordination. Encourage local governments to carry out alliance procurement, and upgrade to national alliance procurement if conditions are met. ...
- Source: drugdu
- 73
- October 9, 2024
14 major consumables enter price reduction period

At the end of September, the National Joint Procurement Platform for High-value Medical Consumables issued the “Notice on the Centralized Maintenance of Cochlear Implants and Peripheral Interventional Medical Consumables”. At present, many provinces have begun to start the historical procurement data reporting work for this national procurement. The reporting subjects are public medical institutions that use cochlear implants and peripheral interventional medical consumables in 2022 and 2023. The deadline is around October 16 and 17. At 15:00 on October 8, the National Joint Procurement Office for High-value Medical Consumables will introduce the system operation through video conferencing, and provide training videos and other materials for use by various medical institutions. Peripheral intervention is one of the few varieties that have not yet been purchased on a large scale. This national procurement is bound to have a major impact on this field. In 2021, Henan’s centralized procurement of neuro-interventional and peripheral ...
- Source: drugdu
- 78
- October 9, 2024
With a dividend rate of 100% and a profit growth rate of nearly 40%, Dong-E-E-Jiao has resumed high growth

In recent days, various stimulus policies designed from the top have been launched, giving the long-dull stock market a long-lost vitality. On September 30, the Shanghai Composite Index closed up 8.06%, standing above 3,300 points, with a cumulative increase of more than 17% in September; the Shenzhen Component Index closed up 10.67%, with a cumulative increase of more than 26% in September; the ChiNext Index closed up 15.36%, with a cumulative increase of more than 37% in September; all set a record for the largest single-day increase in history. On that day, the turnover of the two markets was 2.593 trillion yuan, setting a record high since 2006. The activity of funds has risen unprecedentedly, and once exceeded the carrying capacity of the exchange server during the session. Players in the market are gearing up to “do a big job”. However, the pharmaceutical industry has been subject to many restrictions ...
- Source: drugdu
- 74
- October 9, 2024
【EXPERT Q&A】What is the South African drug export registration process?

Drugdu.com expert’s response: The process of exporting and registering pharmaceutical products in South Africa is a relatively complex and meticulous endeavor, involving multiple stages and documentation requirements. Here is an overview of the process: Ⅰ. Preliminary Preparation Product Classification: Firstly, it is crucial to determine the classification of the pharmaceutical product in South Africa, as different classifications may entail different registration requirements and procedures. Preparation of Technical Documentation: This typically includes detailed information about the product, such as its composition, indications, dosage form, quality standards, as well as technical specifications, design descriptions, and performance test results that demonstrate the product’s safety, efficacy, and performance. Collection of Clinical Data: Depending on the requirements, relevant clinical data must be provided to support the product’s clinical performance and effectiveness. This may encompass clinical trial results, case studies, literature reviews, etc. Corporate Qualification: Ensure that the exporting company has a legal registration status in ...
- Source: drugdu
- 86
- October 9, 2024
Electrophysiology, giants dance wildly

The existing electrophysiology market is very considerable, and the incremental market has unlimited potential. Research institution BTIG predicts that half of atrial fibrillation ablations may be replaced by PFA in the next three years. In the new business of PFA, electrophysiology giants dare not be tired at all. Recently, Boston Scientific announced that it has obtained approval from Japanese regulators for the FARAPULSE™ pulsed field ablation system. Nick Spadea-Anello, president of Boston Scientific Electrophysiology, said that the FARAPULSE PFA system is the most clinically studied PFA system. To date, it has been used to treat more than 125,000 patients worldwide and continues to strengthen its strong safety, effectiveness and efficiency characteristics. “The rapid adoption of the FARAPULSE PFA system, which is now approved in more than 65 countries, demonstrates a paradigm shift in the treatment of paroxysmal atrial fibrillation – an approach that has clinical benefits for both physicians and ...
- Source: drugdu
- 77
- October 8, 2024
Licensed Pharmacists Decreased

According to the National Medical Products Administration’s Licensed Pharmacist Qualification Certification Center, from the end of April to the end of July this year, the cumulative number of licensed pharmacists in the country with valid registration has decreased month-on-month. In April, May, June, and July, the number of registered licensed pharmacists nationwide decreased by 1,940, 685, 4,384, and 88 respectively. In recent years, the number of retail pharmacies in my country has continued to grow. As of the end of December 2023, the number of pharmacies nationwide exceeded 666,000, including 14,792 wholesale enterprises, 6,725 retail chain headquarters, 385,594 retail chain stores, and 281,366 single pharmacies. These data have increased compared to 2022. The total number of retail pharmacies continues to increase, and the society has a strong demand for licensed pharmacists, but the number of registered licensed pharmacists has decreased in several months. The General Department of the State Drug ...
- Source: drugdu
- 105
- October 8, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.